Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
EQ logo EQ
Upturn stock ratingUpturn stock rating
EQ logo

Equillium Inc (EQ)

Upturn stock ratingUpturn stock rating
$0.32
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: EQ (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $1

1 Year Target Price $1

Analysts Price Target For last 52 week
$1Target price
Low$0.27
Current$0.32
high$1.5

Analysis of Past Performance

Type Stock
Historic Profit -44.89%
Avg. Invested days 29
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 11.07M USD
Price to earnings Ratio -
1Y Target Price 1
Price to earnings Ratio -
1Y Target Price 1
Volume (30-day avg) 2
Beta 1.95
52 Weeks Range 0.27 - 1.50
Updated Date 06/29/2025
52 Weeks Range 0.27 - 1.50
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.39

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -46%
Operating Margin (TTM) -47.19%

Management Effectiveness

Return on Assets (TTM) -29.73%
Return on Equity (TTM) -88.32%

Valuation

Trailing PE -
Forward PE 1.53
Enterprise Value -2591079
Price to Sales(TTM) 0.36
Enterprise Value -2591079
Price to Sales(TTM) 0.36
Enterprise Value to Revenue 0.01
Enterprise Value to EBITDA 0.07
Shares Outstanding 35719300
Shares Floating 18292219
Shares Outstanding 35719300
Shares Floating 18292219
Percent Insiders 35.9
Percent Institutions 19.14

Analyst Ratings

Rating 2
Target Price 1
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold 2
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Equillium Inc

stock logo

Company Overview

overview logo History and Background

Equillium, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory diseases. Founded in 2017, they are developing itolizumab, a novel anti-CD6 monoclonal antibody.

business area logo Core Business Areas

  • Therapeutic Development: Focuses on the research, development, and clinical trials of itolizumab for autoimmune and inflammatory diseases.

leadership logo Leadership and Structure

Bruce Steel serves as CEO. The company has a board of directors and is structured around research, clinical development, and business operations.

Top Products and Market Share

overview logo Key Offerings

  • Itolizumab (EQ001): A novel anti-CD6 monoclonal antibody being developed for various autoimmune and inflammatory diseases, including acute graft-versus-host disease (aGVHD), lupus nephritis, and uncontrolled asthma. No current market share as it is still in clinical trials. Competitors include companies developing treatments for these specific indications, such as established immunosuppressants and other biologics (e.g., those by Novartis, Roche, and others).

Market Dynamics

industry overview logo Industry Overview

The autoimmune and inflammatory disease market is a large and growing sector with unmet medical needs. The space is heavily researched with pharmaceutical companies and Biotech companies vying for market share by developing new therapies.

Positioning

Equillium aims to address unmet needs in severe autoimmune and inflammatory diseases with itolizumab, targeting the CD6 pathway. Their competitive advantage lies in the novel mechanism of action of itolizumab.

Total Addressable Market (TAM)

The TAM for autoimmune and inflammatory disease therapies is estimated to be over $100 billion globally. Equillium is targeting niche indications within this broader market, positioning them to potentially capture a significant share if itolizumab is successful in clinical trials and approved.

Upturn SWOT Analysis

Strengths

  • Novel mechanism of action (anti-CD6)
  • Potential for treating a range of autoimmune and inflammatory diseases
  • Experienced management team
  • Orphan drug designation for certain indications

Weaknesses

  • Single product pipeline (itolizumab)
  • Reliance on clinical trial success
  • Limited financial resources compared to larger pharmaceutical companies
  • Lack of established market presence

Opportunities

  • Successful clinical trial outcomes
  • Partnerships with larger pharmaceutical companies
  • Expansion into new indications
  • Regulatory approvals for itolizumab

Threats

  • Clinical trial failures
  • Competition from existing and new therapies
  • Regulatory hurdles
  • Patent expirations
  • Changes in reimbursement policies

Competitors and Market Share

competitor logo Key Competitors

  • NVS
  • RHHBY
  • LLY

Competitive Landscape

Equillium faces competition from established pharmaceutical companies with approved therapies for autoimmune and inflammatory diseases. Their advantage lies in their novel anti-CD6 mechanism.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is primarily tied to advancements in clinical trials and securing funding.

Future Projections: Future growth depends heavily on the success of itolizumab in clinical trials and subsequent regulatory approvals. Analyst estimates would be available on financial data sources.

Recent Initiatives: Focus on advancing clinical trials for aGVHD, lupus nephritis, and uncontrolled asthma and strategic partnership for funding these studies.

Summary

Equillium is a clinical-stage biotech company focusing on itolizumab for autoimmune diseases. Its success hinges on positive clinical trial outcomes. The company faces challenges due to its limited product pipeline and competition from larger pharmaceutical firms. However, successful trials and strategic partnerships could unlock significant growth potential. The anti-CD6 mechanism is unique and if proven effective it could capture significant market share

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Equillium Inc. website
  • SEC filings
  • Company press releases
  • Analyst reports (if available)

Disclaimers:

This analysis is based on publicly available information and is for informational purposes only. It is not financial advice. Market share estimates are approximate and may vary. Investment decisions should be based on thorough research and consultation with a financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Equillium Inc

Exchange NASDAQ
Headquaters La Jolla, CA, United States
IPO Launch date 2018-10-11
Co-Founder, President, CEO & Director Mr. Bruce D. Steel C.F.A.
Sector Healthcare
Industry Biotechnology
Full time employees 35
Full time employees 35

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and in phase 2 clinical trial for the treatment of ulcerative colitis. The company also develops EQ101, first-in-class, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which completed Phase 1/2 to treat cutaneous T cell lymphoma. It serves its products to gastroenterology, dermatology, hematology, transplant science, rheumatology, pulmonology, and oncology areas. The company has a collaboration and license agreement with Biocon SA to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit itolizumab (EQ001) and any pharmaceutical composition or preparation containing or comprising itolizumab (EQ001) that uses Biocon technology or Biocon know-how, or collectively, a Biocon Product. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.